Notification EUROIMMUN AG from Lübeck in Germany, a manufacturer of reagents and automated systems for medical laboratory diagnostics, has developed a PCR test for direct virus detection, in addition to the assays for the detection of antibodies against SARS-CoV-2 (ELISA). The new test is a real-time reverse transcriptase PCR used to detect the genetic material […]
Press release EUROIMMUN AG (Lübeck, Germany), a manufacturer of reagents and instruments for medical laboratory diagnostics, has developed serological tests for detection of antibodies against the novel coronavirus SARS-CoV-2. The two ELISAs enable detection of specific IgA and IgG against the virus in the blood of infected patients. In December 2019 the WHO in China
It all started at a market in Wuhan, China. Within a few weeks, a novel coronavirus, now called 2019-nCoV, spread to at least 15 regions or countries outside of the Chinese mainland. In December 2019, the WHO China Country Office was informed of cases of pneumonia of unknown aetiology (unknown cause) detected in Wuhan City,
On 18 December 2019, our new EUROIMMUN subsidiary in Japan was officially founded after one year of hard work, intensive planning and structuring. Head of this new subsidiary is Cagla Egretaud, who has been working at EUROIMMUN for 20 years. The idea to jointly establish a new subsidiary in Japan, one of the world’s largest
Five years ago, the ICAP initiative on harmonisation and standardisation in the nomenclature of HEp-2 IFA patterns was implemented at the International Workshop on Autoantibodies and Autoimmunity (IWAA) in São Paulo, Brazil. Luis E. C. Andrade, professor at the Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, has been involved from the
